Aprea Therapeutics, Inc. (NASDAQ:APRE) Stock Rated “Moderate Buy” by Sell-Side Brokerages

Shares of Aprea Therapeutics, Inc. (NASDAQ:APRE) have been given a consensus rating of “Moderate Buy” by the six brokerages that are covering the firm, MarketBeat reports. One analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and four have assigned a buy recommendation to the company. The average 1-year price target among analysts that have covered the stock in the last year is $2.80.

APRE has been the topic of a number of recent research reports. Wedbush dropped their target price on Aprea Therapeutics to $3.00 and set an “outperform” rating on the stock in a report on Thursday, August 13th. LADENBURG THALM/SH SH started coverage on Aprea Therapeutics in a report on Wednesday, October 14th. They set a “buy” rating and a $2.00 price target for the company. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Aprea Therapeutics in a research report on Thursday, October 15th.

Aprea Therapeutics Price Performance

APRE opened at $0.52 on Friday. Aprea Therapeutics has a fifty-two week low of $0.41 and a fifty-two week high of $1.49. The firm has a market capitalization of $7.34 million, a PE ratio of -0.74 and a beta of 1.74. The company’s 50-day moving average is $0.66 and its 200 day moving average is $0.74.

Aprea Therapeutics (NASDAQ:APRE) last announced its quarterly earnings results on Wednesday, November 4th. The company reported ($0.09) earnings per share for the quarter, missing the consensus estimate of ($0.07) by ($0.02). As a group, analysts expect that Aprea Therapeutics will post -0.39 EPS for the current year.

About Aprea Therapeutics

Aprea Therapeutics, Inc (NASDAQ: APRE) is a clinical-stage biopharmaceutical company focused on developing targeted therapies for cancer. Its research is centered on small-molecule treatments intended to address molecular abnormalities that contribute to tumor growth and resistance to treatment.

The company’s lead historical program was eprenetapopt, also known as APR-246, an investigational therapy designed to reactivate mutant p53, a tumor-suppressor protein frequently altered in cancer.